Decrease in CD4⁺CD25⁺ and CD8⁺CD28⁺ T cells in interstitial pneumonitis associated with rheumatic disease

References

• Kanai Y, Tokano Y, Tsuda H, Hashimoto H, Okumura K, Hirose S. HLA-DR positive T cells patients with polymyositis/dermat-omyositis. J Rheumatol. 1993;20:77–9.
   PubMedGoogle Scholar
• Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989;170:655–63.
   Google Scholar
• Piguet PF, Collart MA, Grau GE, Sappino AP, Vassalli P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature. 1990;344:245–7.
   Google Scholar
• Zhang Y, TC Lee, Guillemin B, Yu MC, Rom WN. Enhanced IL-I_ beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol. 1993;150:4188–96.
   Google Scholar
• Chen ES, Greenlee BM, Willis-Karp M, Moller DR. Attenuation of inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. Am J Respir Cell Mol Biol. 2001;24:545–55.
   Google Scholar
• Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1 ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine. 1993;5:57–61.
   PubMed Web of Science ®Google Scholar
• Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard 0, Almasy L, et al. Future research directions in idiopathic pul-monary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med. 2002;166: 236–46.
   Google Scholar
• Zhu Z, Homer RJ, Wang Z, Chen 0, Geba GP, Wang J, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subpithelial fibrosis, physiolosic abnor-malities, and eotaxin production. J Clin Invest. 1999;103: 779–88.
   Google Scholar
• Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, et al. Interleukin-13 induces tissue fibrosis by selectively stimu-lating and activating transforming growth factor beta(1). J Exp Med. 2001;194:809–21.
   PubMed Web of Science ®Google Scholar
• Smith RE, Strieter RM, Phan SH, Lukacs NW, Huffnagle GB, Wilke CA, et al. Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury. J Immunol. 1994;153:4704–12.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Kuwano K, Kunitake R, Kawasaki M, Hagimoto N. B7-1, B7-2 and class II MHC molecules in idiopathic pulmonary fibrosis and bronchiolitis obliterans-organizing pneumonia. Eur Respir J. 2000;15: 49–55.
   Google Scholar
• Lee S, Kaneko K, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H. Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol. 1998;37:1334–7.
   PubMedGoogle Scholar
• Hirashima M, Fukazawa T, Abe K, Morita Y, Kusaoi M, Hashimoto H. Expression and activity analyses of CTLA-4 in peripheral blood lymphocytes in systemic lupus erythematosus patients. Lupus. 2004;13:24–31.
   PubMedGoogle Scholar
• Lajaunias F, Ida A, Kikuchi S, Fossati-Jimack L, Martinez-Soria E, Moll T, et al. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus. Arthritis Rheum. 2003;48(6):1612–21.
   Google Scholar
• Suzuki J, Nakano S, Nakiri Y Mitsuo A, Morimoto S, Tokano Y, et al. CD19/22 balance relates to improvement of disease activity in systemic lupus erythematosus. Mod Rheumatol. 2006;16:235–8.
   Google Scholar
• Nakiri Y, Suzuki J, Mitsuo A, Amano H, Morimoto S, Hashimoto H, et al. Expression of CD22 on peripheral B cells in Patients with rheumatoid arthritis: Relation to CD5 positive B cells. Clin Rheumatol. 2007;26:1721–3.
   PubMedGoogle Scholar
• Filaci G, Bacilieri S, Fravega M, Monetti M, Contini P, Indiveri F. Impairment of CD8+ T suppressor cell function in patients with active systemic erythematosus. J Immunol. 2001;166:6452–7.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immu-nologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155: 1151–64.
   Google Scholar
• Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996;184:387–96.
   PubMed Web of Science ®Google Scholar
• Subcommittee for Scleroderma Criteria of the American Com-mittee. Preliminary criteria for the classification of systemic sclerosis. Arthritis Rheum. 1980;23:581–90.
   PubMedGoogle Scholar
• Arnett FC, Edwothy SM, Bloch DA, McShane DJ, Fries FJ, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Kotajima L, Aotsuka S, Sumiya M, Yokohari R, Tojo T, Kasukawa R. Clinical features of patients with juvenile onset mixed connective tissue disease: analysis of date collected in a nationwide collaborative study in Japan. J Rheumatol. 1996;23:1088–94.
   PubMedGoogle Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7,403–7.
   PubMed Web of Science ®Google Scholar
• Iezzi G, Sheidegger D, Lanzavecchia A. Migration and function of anti-primed nonpolarized T lymphocytes in vivo. J Exp Med. 2001;193:987–93.
   Google Scholar
• Masopust D, Vezys V, Usherwood EJ, Cauley LS, Olson S, Marzo AL, et al. Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J Immunol. 2004;172:4875–82.
   Google Scholar
• Suzuki J, Morimoto S, Amano H, Tokano Y, Takasaki Y, Hashimoto H. Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol. 2001;28:2389–91.
   PubMed Web of Science ®Google Scholar
• Fu S, Yopp AC, Mao X, Chen D, Zhanq N, Chen D, et al. CD4±CD25±CD62L±T-regulatory cell subset has optimal sup-pressive and proliferative potential. Am J Transplant. 2004;4:65–78.
   PubMed Web of Science ®Google Scholar
• Mottonen M, Heikkinen J, Mustonen L, Isomaki P, Luukkainen R, Lassila 0. CD4+CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol. 2005;140: 360–7.
   Google Scholar
• Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V. CD251mghtCD4±regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res 'Ther. 2004;6:R335–46.
   PubMedGoogle Scholar
• Kaneko H, Saito K, Hashimoto H, Yagita H, Okumura K, Azuma M. Preferential elimination of CD28+ T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis. Clin Exp Immunol. 1996;106:218–29.
   PubMed Web of Science ®Google Scholar